secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001683168-23-006528
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma shareholders approve director slate, auditor, and 2020 equity plan amendment
--------------------------------------------------------------------------------

- All 7 director nominees elected with majority votes; broker non-votes of 1.4M shares.
- Ratified MaloneBailey LLP as independent auditor for FY2023 (1.7M for, 40k against).
- Approved amendment to 2020 Equity Plan, increasing shares by 745,800 to total 845,800.
- Equity plan amendment also modified annual award limits per Participant.
- Director election and equity plan amendments each had 1.4M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/0001683168-23-006528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer